Danielle M Nash1,2, Maureen Markle-Reid1,3, Kenneth S Brimble4,5, Eric McArthur2, Pavel S Roshanov5, Jeffrey C Fink6, Matthew A Weir2,7, Amit X Garg2,7. 1. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. 2. ICES, Ontario, Canada. 3. School of Nursing, McMaster University, Hamilton, Ontario, Canada. 4. Ontario Renal Network, Toronto, Ontario, Canada. 5. Department of Medicine, McMaster University, Hamilton, Ontario, Canada. 6. School of Medicine, University of Maryland, Baltimore, Maryland, USA. 7. Department of Medicine, Western University, London, Ontario, Canada.
Abstract
BACKGROUND: Clinical guidelines caution against nonsteroidal anti-inflammatory drug (NSAID) use in older adults. The study objective was to quantify the 30-day risk of acute kidney injury (AKI) and hyperkalemia in older adults after NSAID initiation and to develop a model to predict these outcomes. METHODS: We conducted a population-based retrospective cohort study in Ontario, Canada from 2007 to 2015 of patients ≥66 years. We matched 46 107 new NSAID users with 46 107 nonusers with similar baseline health. The primary outcome was 30-day risk of AKI and secondary outcomes were hyperkalemia and all-cause mortality. RESULTS: NSAID use versus nonuse was associated with a higher 30-day risk of AKI {380 [0.82%] versus 272 [0.59%]; odds ratio (OR) 1.41 [95% confidence interval (CI) 1.20-1.65]} and hyperkalemia [184 (0.40%) versus 123 (0.27%); OR 1.50 (95% CI 1.20-1.89); risk difference 0.23% (95% CI 0.13-0.34)]. There was no association between NSAID use and all-cause mortality. A prediction model incorporated six predictors of AKI or hyperkalemia: older age, male gender, lower baseline estimated glomerular filtration rate, higher baseline serum potassium, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use or diuretic use. This model had moderate discrimination [C-statistic 0.72 (95% CI 0.70-0.74)] and good calibration. CONCLUSIONS: In older adults, new NSAID use compared with nonuse was associated with a higher 30-day risk of AKI and hyperkalemia but not all-cause mortality. Prescription NSAID use among many older adults may be safe, but providers should use caution and assess individual risk.
BACKGROUND: Clinical guidelines caution against nonsteroidal anti-inflammatory drug (NSAID) use in older adults. The study objective was to quantify the 30-day risk of acute kidney injury (AKI) and hyperkalemia in older adults after NSAID initiation and to develop a model to predict these outcomes. METHODS: We conducted a population-based retrospective cohort study in Ontario, Canada from 2007 to 2015 of patients ≥66 years. We matched 46 107 new NSAID users with 46 107 nonusers with similar baseline health. The primary outcome was 30-day risk of AKI and secondary outcomes were hyperkalemia and all-cause mortality. RESULTS: NSAID use versus nonuse was associated with a higher 30-day risk of AKI {380 [0.82%] versus 272 [0.59%]; odds ratio (OR) 1.41 [95% confidence interval (CI) 1.20-1.65]} and hyperkalemia [184 (0.40%) versus 123 (0.27%); OR 1.50 (95% CI 1.20-1.89); risk difference 0.23% (95% CI 0.13-0.34)]. There was no association between NSAID use and all-cause mortality. A prediction model incorporated six predictors of AKI or hyperkalemia: older age, male gender, lower baseline estimated glomerular filtration rate, higher baseline serum potassium, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use or diuretic use. This model had moderate discrimination [C-statistic 0.72 (95% CI 0.70-0.74)] and good calibration. CONCLUSIONS: In older adults, new NSAID use compared with nonuse was associated with a higher 30-day risk of AKI and hyperkalemia but not all-cause mortality. Prescription NSAID use among many older adults may be safe, but providers should use caution and assess individual risk.
Authors: E W Steyerberg; F E Harrell; G J Borsboom; M J Eijkemans; Y Vergouwe; J D Habbema Journal: J Clin Epidemiol Date: 2001-08 Impact factor: 6.437
Authors: Michael A Weber; Ernesto L Schiffrin; William B White; Samuel Mann; Lars H Lindholm; John G Kenerson; John M Flack; Barry L Carter; Barry J Materson; C Venkata S Ram; Debbie L Cohen; Jean-Claude Cadet; Roger R Jean-Charles; Sandra Taler; David Kountz; Raymond Townsend; John Chalmers; Agustin J Ramirez; George L Bakris; Jiguang Wang; Aletta E Schutte; John D Bisognano; Rhian M Touyz; Dominic Sica; Stephen B Harrap Journal: J Hypertens Date: 2014-01 Impact factor: 4.844
Authors: Jamie L Fleet; Salimah Z Shariff; Sonja Gandhi; Matthew A Weir; Arsh K Jain; Amit X Garg Journal: BMJ Open Date: 2012-12-28 Impact factor: 2.692
Authors: Danielle M Nash; Scott Brimble; Maureen Markle-Reid; Eric McArthur; Karen Tu; Gihad E Nesrallah; Allan Grill; Amit X Garg Journal: Can J Kidney Health Dis Date: 2017-05-23
Authors: Y Joseph Hwang; Salimah Z Shariff; Sonja Gandhi; Ron Wald; Edward Clark; Jamie L Fleet; Amit X Garg Journal: BMJ Open Date: 2012-11-29 Impact factor: 2.692
Authors: Jonathan G Amatruda; Ronit Katz; Carmen A Peralta; Michelle M Estrella; Harini Sarathy; Linda F Fried; Anne B Newman; Chirag R Parikh; Joachim H Ix; Mark J Sarnak; Michael G Shlipak Journal: J Am Geriatr Soc Date: 2020-12-10 Impact factor: 5.562
Authors: Ziv Harel; Eric McArthur; Nivethika Jeyakumar; Manish M Sood; Amit X Garg; Samuel A Silver; Paul Dorian; Daniel Blum; William Beaubien-Souligny; Andrew T Yan; Sunil V Badve; Brendan Smyth; Min Jun; Racquel Jandoc; Abhijat Kitchlu; Ron Wald Journal: Clin J Am Soc Nephrol Date: 2021-08-18 Impact factor: 10.614